Citations

Clear

66 citation(s) found for "Kottke, B A".

Vesicular stomatitis virus expressing destabilized tumor associated antigens with enhanced MHC class I presentation to improve anti-tumor T cell responses
Kottke, Tim , Wongthida, Phonphimon , Scheulke, Matthew, Vile, Richard G. , Huff, Amanda L. , Evgin, Laura , Thompson, Jill, Driscoll, Christopher B. , Shim, Kevin G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 91.16-91.16

10.4049/jimmunol.204.supp.91.16 Get It

Abstract We have previously shown that vesicular stomatitis virus (VSV) vectors encoding truncated tumor antigens, NRAS, Cytochrome C1, and TYRP1, prime superior systemic anti-tumor T cell responses and provide enhanced therapeutic benefit compared to vectors expressing full-length forms of the protein. Mapping of the roughly 20 amino C-terminal truncated regions onto structural domains of each protein suggested the truncations disrupted the stability and localization of each protein. Indeed, immunofluorescent staining and radiolabeled pulse chase found that truncated TYRP1 (ΔTYRP1) had an altered localization pattern and a significantly reduced half-life compared to full-length TYRP1. Thus, we hypothesized that expression of destabilized antigens from VSV would provide superior therapy compared to expression of wild-type antigens. To test this, we introduced point-mutations into structurally important domains of the model antigen ovalbumin (OVA). We identified one mutant which was significantly destabilized (OVAmut), which resulted in enhanced MHC Class I presentation of the immunogenic SIINFEKL epitope on transfected cell in vitro. Expression of OVAmut resulted in better recognition by cognate CD8 OTI T cells, enhanced T cell activation, proliferation, and effector cytokine production. Finally, a VSV vector expressing OVmut was better able to prime OTI T cells in vitro as well as in vivo. Ongoing studies aim to identify the changes in the quantity and repertoire of immunogenic epitopes presented from cells infected with VSV vectors expressing destabilized antigens. These studies provide insight into the capacity of the VSV platform to successfully encode unstable antigens with the goal improve immunogenic responses.
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
Evgin, Laura , Kottke, Tim , Tonne, Jason M., Thompson, Jill , Huff, Amanda L. , Vloten, Jacob P. van , Moore, Madelyn , Michael, Josefine, Driscoll, Christopher B. , Pulido, José S. , Swanson, Eric , Kennedy, Richard B. , Loghmani, Houra , Sánchez-Pérez, Luis, Olivier, Gloria , Harrington, Kevin J. , Pandha, Hardev , Melcher, Alan , Díaz, Rosa María, Vile, Richard G. , Tonne, Jason , van Vloten, Jacob , Driscoll, Christopher , Pulido, Jose, Kennedy, Richard , Coffey, Matt C. , Olivier, Gloria , Harrington, Kevin , Melcher, Alan A , Swanson, Eric

Mayo Clinic

Science Translational Medicine | April 13, 2022 | Volume: 14 | Issue: 640 | Pages: No page available

10.1126/scitranslmed.abn2231 | PMID 35417192 Get It

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically delivered OVs and CAR T cells in immunocompetent mouse models, we have defined a mechanism by which OVs can potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. We show that stimulation of the native T cell receptor (TCR) with viral or virally encoded epitopes gives rise to enhanced proliferation, CAR-directed antitumor function, and distinct memory phenotypes. In vivo expansion of dual-specific (DS) CAR T cells was leveraged by in vitro preloading with oncolytic vesicular stomatitis virus (VSV) or reovirus, allowing for a further in vivo expansion and reactivation of T cells by homologous boosting. This treatment led to prolonged survival of mice with subcutaneous melanoma and intracranial glioma tumors. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens and was associated with greater CAR-directed cytokine production. Our data highlight the utility of combining OV and CAR T cell therapy and show that stimulation of the native TCR can be exploited to enhance CAR T cell activity and efficacy in mice.
Impact of Risk Factor Changes in a Population
Wu, Lambert A., Brekke, Lee , Brekke, Mark J., Kottke, Thomas E.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 103 | Issue: suppl_1 | Pages: 1358-1358

10.1161/circ.103.suppl_1.9998-39 Get It

P39 Background: Risk factor trends in the United States are not favorable. We determined the potential population impact of risk factor trends versus achieving Healthy People 2010 goals. Methods: Four possible risk factor scenarios were defined for the year 2020. Scenarios were based on current and past risk factor levels and current national goals: 1) Current risk factor levels in Olmsted County, MN; 2) Continued rise in diabetes and smoking rates; 3) #2 plus loss of blood pressure and cholesterol control; 4)Population meets Healthy People 2010 goals. Risk factors were assigned stochastically to the year 2000 Olmsted County, MN population, ages 30-83. Framingham-based risk functions were then used to calculate cardiovascular (CVD) event rates under each scenario. Conclusions: If diabetes and smoking continue to rise, and hypertension and cholesterol rise to historically high levels, CVD rates could rise as much as 75%. In contrast, meeting Healthy People 2010 goals would reduce CVD rates by 49%. Table 1.
Inactivation of Replication-Competent Vesicular Stomatitis Virus as SARS-CoV-2 Surrogate on Common Surfaces by Disinfectants
Kottke, Timothy, Shah, Aditya , Vile, Richard G. , Rizza, Stacey A. , Pope, Zachary C, Kottke, Timothy J, Pope, Zachary

Mayo Clinic

International Journal of Environmental Research and Public Health | July 20, 2021 | Volume: 18 | Issue: 14 | Pages: 7714

10.3390/ijerph18147714 | PMID 34300163 Get It

Surface disinfection is part of a larger mitigation strategy to prevent the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus causing coronavirus disease-2019 (COVID-19). Research evaluating the time, nature, and extent of surface disinfection of replication-competent viruses is needed. We evaluated the efficacy of two disinfectants against a replication-competent SARS-CoV-2 surrogate on three common public surfaces. Vesicular stomatitis virus expressing green fluorescent protein (VSV-GFP) was our replication-competent SARS-CoV-2 surrogate. Disinfection occurred using Super Sani-Cloth Germicidal Disposable Wipes and Oxivir Tb spray per manufacturer instructions to test the efficacy at reducing the presence, viability, and later replication of VSV-GFP on stainless steel, laminate wood, and porcelain surfaces using standardized methods after recovery and toxicity testing. During the main trials, we placed 100 µL spots of VSV-GFP at viral titers of 108, 107, and 106 PFU/mL on each surface prior to disinfection. Trials were completed in triplicate and post-disinfection measurements on each surface were compared to the measurements of non-disinfected surfaces. Disinfectants were considered efficacious when ≥3-log10 reduction in the number of infectious VSV-GFP virus units was observed on a given surface during all trials. Both disinfectants produced a ≥3.23-log10 reduction in infectious VSV-GFP virus unit numbers, with all trials showing no viable, replication-competent VSV-GFP present on any tested surface. The two disinfectants eliminated the presence, viability, and later replication of VSV-GFP, our SARS-CoV-2 surrogate, on all surfaces. This information suggests that, if following manufacturer instructions, overcleaning surfaces with multiple disinfectant solutions may be unnecessary.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra , Bierle, Dennis M. , Anderson, Ryan J. , Arndt, Lori L., Arndt, Richard , Culbertson, Tracy L, Borgen, Molly J. Destro, Hanson, Sara N. , Kennedy, Brian , Kottke, Brian B, Larsen, Jennifer J., Ramar, Priya , Rosedahl, Jordan K., Seville, Maria Teresa , Speicher, Leigh L. , Tulledge‐Scheitel, Sidna M. , Wilker, Caroline G. , Arndt, Richard F, Destro Borgen, Molly J, Kennedy, Brian D, Tulledge-Scheitel, Sidna M, Razonable, Raymund R , Ganesh, Ravindra , Philpot, Lindsey M. , Razonable, Raymund R.

Mayo Clinic

The Journal of Infectious Diseases | July 17, 2021 | Volume: 224 | Issue: 8 | Pages: 1278-1286

10.1093/infdis/jiab377 | PMID 34279629 Get It

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. Methods Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19–related hospitalizations were compared between the groups. Results The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19–related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19–related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9–2.2] and 1.6 [.8–2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. Conclusions This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Attempts at Changing Diet and Exercise to Lower Risk of Coronary Heart Disease and Stroke: Who’s Doing What in the Community?
Brekke, M, Brandel, Catherine L., DeBoer, Stephen W., Thomas, Randal J. , Kottke, Thomas E.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 103 | Issue: suppl_1 | Pages: 1368-1368

10.1161/circ.103.suppl_1.9998-90 Get It

P90 Background and Methods:While only a minority of the population follows a low fat diet and does daily physical activity, it is unclear how much of the population is trying to improve these lifestyle habits. We carried out a telephone survey of 1232 adults, >20 years of age, from Olmsted County, MN to assess their attempts at improving their dietary and exercise habits to lower their risk of developing heart disease and stroke. Results: Fifty-nine percent of respondents reported making attempts to improve exercise habits, 71% reported attempts to improve their eating habits, and 50% reported trying to improve both habits. In all, 80% reported trying to improve exercise and/or dietary habits. Of those trying to change exercise habits, 69% reported at least some physical activity on a daily basis (Pearson correlation = 0.34). Of those attempting to change dietary habits, 31% reported eating at least five servings of fruits and vegetables each day (Pearson correlation = 0.14). After multivariate adjustment, attempts to change diet or exercise were highest in persons trying to lose or maintain weight, and persons who reported having received previous physician advice to change diet and exercise habits. Conclusions: The majority of people in Olmsted County, MN are attempting to change their exercise and dietary habits to reduce their risk of coronary heart disease and stroke. Still, only a minority are meeting recommended dietary and physical activity goals. Since most people are in the action phase of exercise and dietary behavioral change, health promotion messages should include information on how best to improve and maintain these health habits. Furthermore, since report of receiving physician advice is correlated with attempts to change lifestyle habits and since only 44% of the population reports receiving such advice, there is an opportunity for health care providers to impact their patients lives by advising them on how to make improvements in their dietary and exercise habits.
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors
Wongthida, Phonphimon , Schuelke, Matthew , Driscoll, Christopher B. , Kottke, Timothy, Thompson, Jill , Tonne, Jason M., Wetmore, Cynthia, Davies, James A. , Parker, Alan L. , Evgin, Laura , Vile, Richard G. , Schuelke, Matthew R, Thompson, Jill M, Tonne, Jason , Stone, Cathy, Huff, Amanda L. , Parker, Alan L , Driscoll, Christopher , Stone, Cathy

Mayo Clinic

Neuro-Oncology | May 21, 2020 | Volume: 22 | Issue: 12 | Pages: 1757-1770

10.1093/neuonc/noaa126 | PMID 32459315 Get It

Abstract Background Diffuse midline glioma, formerly DIPG (diffuse intrinsic pontine glioma), is the deadliest pediatric brainstem tumor with median survival of less than one year. Here, we investigated (i) whether direct delivery of adenovirus-expressing cluster of differentiation (CD)40 ligand (Ad-CD40L) to brainstem tumors would induce immune-mediated tumor clearance and (ii) if so, whether therapy would be associated with a manageable toxicity due to immune-mediated inflammation in the brainstem. Methods Syngeneic gliomas in the brainstems of immunocompetent mice were treated with Ad-CD40L and survival, toxicity, and immune profiles determined. A clinically translatable vector, whose replication would be tightly restricted to tumor cells, rAd-Δ24-CD40L, was tested in human patient–derived diffuse midline gliomas and immunocompetent models. Results Expression of Ad-CD40L restricted to brainstem gliomas by pre-infection induced complete rejection, associated with immune cell infiltration, of which CD4+ T cells were critical for therapy. Direct intratumoral injection of Ad-CD40L into established brainstem tumors improved survival and induced some complete cures but with some acute toxicity. RNA-sequencing analysis showed that Ad-CD40L therapy induced neuroinflammatory immune responses associated with interleukin (IL)-6, IL-1β, and tumor necrosis factor α. Therefore, to generate a vector whose replication, and transgene expression, would be tightly restricted to tumor cells, we constructed rAd-Δ24-CD40L, the backbone of which has already entered clinical trials for diffuse midline gliomas. Direct intratumoral injection of rAd-Δ24-CD40L, with systemic blockade of IL-6 and IL-1β, generated significant numbers of cures with readily manageable toxicity. Conclusions Virus-mediated delivery of CD40L has the potential to be effective in treating diffuse midline gliomas without obligatory neuroinflammation-associated toxicity.
Diabetes, Obesity and Hyperlipidemias II (Proceedings of the 3rd European Meeting on Metabolism held in Padua on May 28-30, 1981), G. Crepaldi, P. J. Lefèbvre, and D. J. Galton, Eds. Academic Press, Inc. (London) Ltd., 24-28 Oval Road, London NW1 7DX, U.K
Kottke, Bruce A.

Mayo Clinic

Clinical Chemistry | January 20, 2020 | Volume: 30 | Issue: 5 | Pages: 822-822

10.1093/clinchem/30.5.822 Get It

Apolipoprotein B Quantified by Particle-Concentration Fluorescence Immunoassay
Hallaway, Brenda J., Rastogi, Amita, Kottke, B A

Mayo Clinic

Clinical Chemistry | January 13, 2020 | Volume: 38 | Issue: 12 | Pages: 2387-2391

10.1093/clinchem/38.12.2387 Get It

Abstract We have developed a particle-concentration fluorescence immunoassay (PCFIA) for estimating apolipoprotein (apo) B concentrations in plasma. A two-step antigen-detection system with a polyclonal antibody to apo B bound to carboxyl-polystyrene particles binds the antigen, and a fluorescein-labeled monoclonal antibody detects the bound apo B. Narrow-cut low-density lipoproteins (d = 1.03-1.05 kg/L) were used as the primary standard. The assay compares well with the enzyme-linked immunosorbent assay. The PCFIA gives parallel responses with low-density lipoprotein, very-low-density lipoproteins, and plasma samples, and can be fully automated and completed in 3 h. In a pilot study of patients with diabetes, coronary artery disease (CAD), or both, we found statistically significant differences in apo B concentrations for patients with both CAD and diabetes compared with those for patients with diabetes alone or for control subjects (P < 0.01).
Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis
Kottke, Timothy, Martins, L. Miguel , Kaufmann, Scott H. , Earnshaw, William C.

Mayo Clinic

Blood | October 14, 2019 | Volume: 92 | Issue: 9 | Pages: 3042-3049

10.1182/blood.v92.9.3042 Get It

Abstract Treatment of HL-60 human leukemia cells with etoposide induces apoptotic cell death and activation of at least 18 electrophoretically distinct cysteine-dependent aspartate-directed protease (caspase) isoforms, several of which differ only in their isoelectric points. The purpose of the present study was to determine whether activated caspases are phosphorylated. Phosphatase treatment of cytosolic extracts containing active caspases followed by affinity labeling with N-(N-benzyloxycarbonylglutamyl-N-biotinyllysyl)aspartic acid [(2,6-dimethylbenzoyl)oxy] methyl ketone (Z-EK(bio)D-aomk) showed a mobility shift in several of the labeled species, suggesting that phosphorylated forms of these enzymes are present in the extracts. Metabolic labeling with 32P followed by etoposide treatment and subsequent affinity purification of affinity-labeled caspases confirmed that at least three caspase species were phosphorylated. To detect effects of the phosphorylation on enzymatic activity, caspase-mediated cleavage of aspartylglutamylvalinylaspartyl-7-amino-4-trifluoromethylcoumarin (DEVD-AFC) and poly(ADP-ribose) polymerase (PARP) by phosphorylated and dephosphorylated extracts was measured. No significant changes in Km or vmax were detected using DEVD-AFC. In contrast, a slight, but significant enhancement of PARP cleavage was observed in dephosphorylated extracts, suggesting that phosphorylation of active caspases could have an inhibitory effect on enzyme activity. These observations, which provide the first evidence that caspases are phosphoproteins, suggest that caspases may be targets for some of the growing list of protein kinases that are involved in apoptotic events. © 1998 by The American Society of Hematology.